PMID- 32432360
OWN - NLM
STAT- MEDLINE
DCOM- 20210602
LR  - 20210602
IS  - 1932-8737 (Electronic)
IS  - 0160-9289 (Print)
IS  - 0160-9289 (Linking)
VI  - 43
IP  - 7
DP  - 2020 Jul
TI  - Statin use in patients with non-HMGCR idiopathic inflammatory myopathies: A 
      retrospective study.
PG  - 732-742
LID - 10.1002/clc.23375 [doi]
AB  - BACKGROUND: Statins are the most widely used lipid lowering therapies which 
      reduce cardiovascular risk, but are associated with muscular adverse events 
      (AEs). Idiopathic inflammatory myopathies (IIM) are autoimmune diseases of the 
      muscle with higher risk of cardiovascular disease. More data is needed regarding 
      statin safety in patients with intrinsic muscle disease such as IIM. HYPOTHESIS: 
      Statins are tolerated in patients with IIM without leading to significant 
      increase in muscular AEs. METHODS: Statin use was retrospectively examined in a 
      longitudinal IIM cohort. Safety analysis included assessment of muscular and 
      nonmuscular AEs by chart review. IIM patients receiving a statin during the 
      cohort follow-up period were matched to IIM patients not receiving a statin for 
      comparative analysis of longitudinal outcomes. RESULTS: 33/214 patients had a 
      history of statin use. 63% started for primary prevention, while others were 
      started for clinical ASCVD events, vascular surgery, IIM related heart failure, 
      and cardiac transplantation. A high intensity statin was used in nine patients 
      with non-HMGCR myositis, and tolerated in 8/9 patients. Statin related muscular 
      AE was noted in three patients. There were no cases of rhabdomyolysis, or statin 
      related nonmuscular AEs in a median observation period of 5 years. In patients 
      newly started on statins during cohort follow-up (n = 7) there was no change in 
      disease activity after statin initiation. Long term outcomes were not different 
      between statin and nonstatin IIM control groups. CONCLUSION: Statins were well 
      tolerated in patients with non-HMGCR positive IIM. Given the accelerated 
      atherosclerotic risk in IIM patients, further prospective studies of statin 
      safety in IIM patients are warranted.
CI  - (c) 2020 The Authors. Clinical Cardiology published by Wiley Periodicals, Inc.
FAU - Bae, Sangmee Sharon
AU  - Bae SS
AUID- ORCID: 0000-0002-7216-7219
AD  - Division of Rheumatology, University of California Los Angeles, Los Angeles, 
      California, USA.
FAU - Oganesian, Buzand
AU  - Oganesian B
AD  - Division of Rheumatology, University of California Los Angeles, Los Angeles, 
      California, USA.
FAU - Golub, Ilana
AU  - Golub I
AD  - Division of Rheumatology, University of California Los Angeles, Los Angeles, 
      California, USA.
FAU - Charles-Schoeman, Christina
AU  - Charles-Schoeman C
AD  - Division of Rheumatology, University of California Los Angeles, Los Angeles, 
      California, USA.
LA  - eng
GR  - R01HL123064/HL/NHLBI NIH HHS/United States
GR  - 5K23HL094834/HL/NHLBI NIH HHS/United States
GR  - R01HL123064/HL/NHLBI NIH HHS/United States
GR  - 5K23HL094834/HL/NHLBI NIH HHS/United States
PT  - Journal Article
DEP - 20200520
PL  - United States
TA  - Clin Cardiol
JT  - Clinical cardiology
JID - 7903272
RN  - 0 (Autoantibodies)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - EC 1.1.1.- (HMGCR protein, human)
RN  - EC 1.1.1.- (Hydroxymethylglutaryl CoA Reductases)
SB  - IM
MH  - Aged
MH  - Atherosclerosis/prevention & control
MH  - Autoantibodies/blood
MH  - Female
MH  - Humans
MH  - Hydroxymethylglutaryl CoA Reductases/*blood
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Myositis/*drug therapy/*enzymology
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Treatment Outcome
PMC - PMC7368310
OTO - NOTNLM
OT  - idiopathic inflammatory myopathy
OT  - muscle adverse events
OT  - retrospective study
OT  - statin use
COIS- All other authors have neither conflicts of interest nor conflicts relating to 
      financial support or other benefits from commercial sources for the work 
      supported in this manuscript.
EDAT- 2020/05/21 06:00
MHDA- 2021/06/03 06:00
PMCR- 2020/05/20
CRDT- 2020/05/21 06:00
PHST- 2020/02/02 00:00 [received]
PHST- 2020/03/31 00:00 [revised]
PHST- 2020/04/03 00:00 [accepted]
PHST- 2020/05/21 06:00 [pubmed]
PHST- 2021/06/03 06:00 [medline]
PHST- 2020/05/21 06:00 [entrez]
PHST- 2020/05/20 00:00 [pmc-release]
AID - CLC23375 [pii]
AID - 10.1002/clc.23375 [doi]
PST - ppublish
SO  - Clin Cardiol. 2020 Jul;43(7):732-742. doi: 10.1002/clc.23375. Epub 2020 May 20.